regeneron pharmaceuticals semaglutide announced on January 30, 2026, that its experimental obesity drug candidate delivers significant Semaglutide / B12 GLP-1 Injection

Hypothyroid patients may have an increased risk for digitalis toxicity

The medication activates GLP-1 (glucagon-like peptide-1) receptors to promote insulin release, slow gastric emptying, and suppress appetite

The most common side effects were gastrointestinal, the company added, with the vast majority being mild to moderate in severity

Missing doses can reduce their impact, disrupt appetite control, and lead to weight gain

How do I feel on this medication

This perspective promotes the development of integrative medicine models, emphasizing the intrinsic connection between somatic and psychiatric symptoms and suggesting the need for multidisciplinary collaboration between gastroenterology and psychiatry